Home - Investor Relations
Investor Relations
| Sl No. | Name of Director | Designation |
|---|---|---|
| 1 | Mr. Dwarika Prasad Tantia | Chairman & Whole-time Director |
| 2 | Dr. Om Tantia | Managing Director |
| 3 | Dr. Aruna Tantia | Non-Executive Director |
| 4 | Dr. Ghanshyam Goyal | Non-Executive Director |
| 5 | Mr. Anurag Tantia | Whole-time Director |
| 6 | Mr. Amrendra Prasad Verma | Independent Director |
| 7 | Mr. Kashi Prasad Khandelwal | Independent Director |
| 8 | Mr. Deepak Pramanik | Independent Director |
| 9 | Dr. Tapti Sen | Independent Director |
| 10 | Mr. Hari Modi | Independent Director |
| Policy Document | Download |
|---|---|
| GHL-Board Performance Appraisal Policy |  |
| GHL-Code of Conduct for Board and Senior Mangers | |
| GHL-Code of Conduct for Prevention of Insider Trading | |
| GHL-Code of Corporate Disclosure for PIT | |
| GHL-Criteria for making payment to Non Executive Directors | |
| GHL-CSR Policy | |
| GHL-Diversity Policy | |
| GHL-Dividend Policy | |
| GHL-Familiarisation Programme for IDs | |
| GHL-Materiality Policy for Disclosure in Offer Documents | |
| GHL-Materiality Subsidiary Policy | |
| GHL-Nomination and Remuneration Policy | |
| GHL-Policy for Determining Materiality for Disclosure | |
| GHL-Policy for Document Retention and Archival | |
| GHL-Policy on Succession Planning | |
| GHL-Related Party Transactions Policy | |
| GHL-Risk Management Policy | |
| GHL-Sexual Harassment Policy | |
| GHL-Terms of Appointment of Independent Director | |
| GHL-Vigil Mechanism Policy | |
| Financial Year | Download |
|---|---|
| Financials | |
| Documents | Download |
|---|---|
| MGT-7 (Annual Return)- 2022-23 | |
| MGT-7 (Annual Return)- 2021-22 | |
| MGT-7 (Annual Return)- 2020-21 | |
| Sl. No. | Particulars | Download PDF |
|---|---|---|
| A1. | Offer Agreement | |
| A2. | Amendment to Offer Agreement | |
| A3. | Registrar Agreement | |
| A4. | Cash Escrow and Sponsor Bank Agreement | |
| A5. | Share Escrow Agreement | |
| A6. | Syndicate Agreement | |
| A7. | Underwriting Agreement | |
| A8. | Shareholder Agreement | |
| A9. | Non- Disposal Agreement | |
| A10. | Earmarking Agreement | |
| Sl. No. | Particulars | Download PDF | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B1. | Copy of MOA and AOA | |
||||||||||||||||||||||||||||||||
| B2. | Certificate of Incorporation | |
||||||||||||||||||||||||||||||||
| B3. | Board and Shareholder Resolution approving the Offer and other related matters | |
||||||||||||||||||||||||||||||||
| B4. | Board and IPO Committee Resolution approving the DRHP/RHP | |
||||||||||||||||||||||||||||||||
| B5. |
Annual Reports
|
|
||||||||||||||||||||||||||||||||
| B6. | The examination report of the Statutory Auditor on our Restated Standalone Financial Information, included in this RHP | |
||||||||||||||||||||||||||||||||
| B7. | The examination report of the Statutory Auditor on our Restated Consolidated Financial Information, included in this RHP | |
||||||||||||||||||||||||||||||||
| B8. | Statement of special tax benefits | |
||||||||||||||||||||||||||||||||
| B9. | Certificate from Singhi & Co., Chartered Accountants in relation to the KPIs. | |
||||||||||||||||||||||||||||||||
| B10. |
Written consent
|
|
||||||||||||||||||||||||||||||||
| B11. | Consent From CRISIL to reproduce report | |
||||||||||||||||||||||||||||||||
| B12. | Written consent from Singhi & Co., Chartered Accountants on various aspects | |
||||||||||||||||||||||||||||||||
| B13. | Written consent of independent chartered accountants | |
||||||||||||||||||||||||||||||||
| B14. | CRISIL Industry Report | |
||||||||||||||||||||||||||||||||
| B15. | Engagement Letter with CRISIL | |
||||||||||||||||||||||||||||||||
| B16. | Consent letters from the Selling Shareholders authorizing participation in the offer | |
||||||||||||||||||||||||||||||||
| B17. | Executive Directors' remuneration agreement and resolutions | |
||||||||||||||||||||||||||||||||
| B18. | Due diligence certificate | |
||||||||||||||||||||||||||||||||
| B19. | In–principle approvals | |
||||||||||||||||||||||||||||||||
| B20. | Tripartite agreement- NSDL | |
||||||||||||||||||||||||||||||||
| B21. | Tripartite agreement- CSDL | |
||||||||||||||||||||||||||||||||
| B22. | SEBI final observation letter | |
||||||||||||||||||||||||||||||||
| B23. | Board Resolution approving the RHP | |
||||||||||||||||||||||||||||||||
| B24. | SEBI exemption letter | |
||||||||||||||||||||||||||||||||
| B25. | Valid Peer Review Certificate | |
| Industry Report | Download PDF |
|---|---|
| Assessment of the healthcare delivery industry in India report | |
As per the Materiality Policy adopted by the Board of Directors of the Company the outstanding dues to the material creditors is NIL as on June 30, 2022.
Audit Committee
| Sl No. | Name | Position | Category |
|---|---|---|---|
| 1 | Mr. Deepak Pramanik | Chairman | Non-Executive – Independent Director |
| 2 | Mr. Kashi Prasad Khandelwal | Member | Non-Executive – Independent Director |
| 3 | Mr. Amrendra Prasad Verma | Member | Non-Executive – Independent Director |
Stakeholders Relationship Committee
| Sl No. | Name | Position | Category |
|---|---|---|---|
| 1 | Mr. Hari Modi | Chairman | Non-Executive Independent Director |
| 2 | Dr. Tapti Sen | Member | Non-Executive Independent Director |
| 3 | Mr. Anurag Tantia | Member | Whole-time Director |
Nomination and Remuneration Committee
| Sl No. | Name | Position | Category |
|---|---|---|---|
| 1 | Mr. Kashi Prasad Khandelwal | Chairman | Non-Executive – Independent Director |
| 2 | Dr. Tapti Sen | Member | Non-Executive – Independent Director |
| 3 | Mr. Hari Modi | Member | Non-Executive – Independent Director |
Risk Management Committee
| Sl No. | Name | Position | Category |
|---|---|---|---|
| 1 | Mr. Amrendra Prasad Verma | Chairman | Non-Executive – Independent Director |
| 2 | Mr. Kashi Prasad Khandelwal | Member | Non-Executive – Independent Director |
| 3 | Mr. Anurag Tantia | Member | Whole-time Director |
| 4 | Mrs Kriti Tantia | Permanent Invitee | CFO |
Corporate Social Responsibility Committee
| Sl No. | Name | Position | Category |
|---|---|---|---|
| 1 | Mr. Dwarika Prasad Tantia | Chairman | Chairman & Whole-time Director |
| 2 | Dr. Aruna Tantia | Member | Non-Executive – Non-Independent Director |
| 3 | Dr. Tapti Sen | Member | Non-Executive – Independent Director |
IPO Committee
| Sl No. | Name | Position | Category |
|---|---|---|---|
| 1 | Mr. Dwarika Prasad Tantia | Chairman | Chairman & Whole-time Director |
| 2 | Mr. Kashi Prasad Khandelwal | Member | Non-Executive – Independent Director |
| 3 | Mr. Anurag Tantia | Member | Whole-time Director |
INVESTOR HELPDESK:
Company Secretary and Compliance Officer
GPT Healthcare Limited
Mr. Ankur Sharma
GPT Centre, JC-25, Sector-III
Salt Lake, Kolkata - 700 106
Tel: +91 33 4050 7000
West Bengal, India
E-mail: ghl.cosec@gptgroup.co.in
Registrar & Share Transfer Agent
MUMBAI
Link Intime India Pvt. Ltd.
C-101, 247 Park,
LBS MARG, Vikhroli (West)
Mumbai - 400083
Tel: +91 22 49186200
E-mail: gpthealthcare.ipo@linkintime.co.in
| Date | Document | Download |
|---|---|---|
| 09.04.2024 | Newspaper Publication of Postal Ballot Notice | |
| 08.04.2024 | Notice of Postal Ballot | |
| 28.03.2024 | Closure of Trading Window | |
| 23.03.2024 | Transcript of Conference Call held on Thursday, March 21, 2024. | |
| 21.03.2024 | Revision of Outcome of Board Meeting held on March 19, 2024 | |
| 21.03.2024 | Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 | |
| 21.03.2024 | Audio Recording of Q3 Earnings call held today i.e March 21, 2024 | |
| 20.03.2024 | Newspaper Publication of Q3 Financial Results and Notice of Record Date | |
| 19.03.2024 | Revised Notice of Record Date | |
| 19.03.2024 | Submission of Investors Presentation Q3FY24 | |
| 19.03.2024 | Intimation in terms of Regulation 30(5) of the SEBI (Listing Obligations and DisclosureRequirements) Regulations, 2015. | |
| 19.03.2024 | Press Release on Q3 FY 2024 Financial Results | |
| 19.03.2024 | Declaration of Second Interim Dividend and Notice of Record Date | |
| 19.03.2024 | Submission of Un-AuditedFinancial Results for theQuarter and Nine Months ended December 31, 2023 | |
| 19.03.2024 | Outcome of Board Meeting held on March 19, 2024. | |
| 18.03.2024 | Intimation of Earnings Call to discuss the financial performance of the Company for the 3rd quarter ended December 31, 2023 | |
| 17.03.2024 | Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. | |
| 12.03.2024 | Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI(LODR), Regulations 2015 | |
| 11.03.2024 | Intimation of Board Meeting pursuant to Regulations 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to be held on March 19, 2024. | |
| 02.03.2024 | Closure of Trading Window | |
| Name of the Company | Download |
|---|---|
| GPT Estate Private Limited | |
| TM Medicare Private Limited | |
Coming Soon
Coming Soon